Hours

Minutes

Seconds

-40%

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Valuation: Guizhou Yibai Pharmaceutical Co., Ltd.

Market Cap	258.07Cr 38Cr 33Cr 30Cr 28Cr 53Cr 3.6TCr 54Cr 357.57Cr 139.67Cr 1.76TCr 143.09Cr 140.06Cr 6.11TCr	P/E Ratio 2024	-8.86x	P/E Ratio 2025	-9.48x
Enterprise Value	279.78Cr 41Cr 36Cr 33Cr 31Cr 58Cr 3.91TCr 58Cr 387.65Cr 151.42Cr 1.91TCr 155.13Cr 151.84Cr 6.62TCr	EV / Sales 2024	1.48x	EV / Sales 2025	1.79x
Free-Float	67.99%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Guizhou Yibai Pharmaceutical Co., Ltd.

Timeframe

Style

Dynamic Chart

Latest news : Guizhou Yibai Pharmaceutical Co., Ltd.

23/04	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
29/25/29	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
18/25/18	Authorities Lift Suspension Order on Yibai Pharma's Production, Sales of Children's Cough Syrup	MT
20/25/20	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
06/25/06	Yibai Pharmaceutical Gets Order to Suspend Marketing of Children's Cough Syrup	MT
25/25/25	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
28/24/28	Guizhou Yibai Pharmaceutical Co., Ltd. 's Equity Buyback announced on November 29, 2023 has expired.	CI
25/24/25	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
10/24/10	Tranche Update on Guizhou Yibai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.	CI
09/24/09	Guizhou Yibai Pharmaceutical CFO Steps Down; Successor Named	MT
04/24/04	Guizhou Yibai Pharmaceutical Gets China Approval for Multiple, Non-Hodgkin's Lymphoma Drug	MT
23/24/23	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
03/24/03	Tranche Update on Guizhou Yibai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.	CI

More news

Managers and Directors: Guizhou Yibai Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Ya Qi Dou CEO	Chief Executive Officer	42	13/05/2021
Xianti Zeng DFI	Director of Finance/CFO	52	06/09/2024
Zhi Wei Wang PRN	Corporate Officer/Principal	56	17/09/2019

Director	Title	Age	Since
Qi Ling Dou CHM	Chairman	66	22/01/2009
Zhi Wei Wang BRD	Director/Board Member	56	21/02/2011
Ya Qi Dou BRD	Director/Board Member	42	03/01/2019

More insiders

Guizhou Yibai Pharmaceutical Co Ltd is a China-based company principally engaged in pharmaceutical industry, medical services, and big health industry businesses. The pharmaceutical industry business is mainly engaged in the research and development, production and sales of chemical drugs, traditional Chinese medicines, biological drugs and other drugs. The medical service business is mainly engaged in the operation and management of comprehensive hospitals, tumor specialty hospitals, and tumor radiotherapy centers. The big health industry business is mainly engaged in the development, research, production and sales of big health products featuring Miao medicine. The Company mainly operates its businesses in the domestic market.

Employees

4,832

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
15/26/15	3.290 ¥	0.00%	1,50,57,100
12/26/12	3.290 ¥	+1.23%	1,65,88,380
11/26/11	3.250 ¥	-1.81%	1,43,54,220
10/26/10	3.310 ¥	-0.60%	1,44,07,180
09/26/09	3.330 ¥	-0.60%	1,77,10,608

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Shanghai S.E. Other stock markets 15/06/2026			5-day change	1st Jan Change
3.290 ^CNY	0.00%		-4.64%	-17.34%

1 week	-4.64%
Current month	-7.06%
1 month	-17.34%
3 months	-17.54%
6 months	-16.07%
Current year	-17.34%

1 week	3.18	3.39
1 month	3.18	3.92
Current year	3.18	5.27
1 year	3.18	5.27
3 years	2.76	6.15
5 years	2.76	8.8
10 years	2.76	20.3

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU YIBAI PHARMACEUTICAL CO., LTD.	0.00%	-4.64%	-16.50%	-36.97%	38Cr
ELI LILLY AND COMPANY	-0.65%	-1.76%	+39.80%	+148.71%	1,01000Cr
JOHNSON & JOHNSON	-2.02%	+1.65%	+52.04%	+44.14%	58TCr
ABBVIE INC.	-2.62%	-0.79%	+15.95%	+62.86%	40TCr
ROCHE HOLDING AG	-0.46%	0.00%	+21.28%	+19.14%	33TCr
NOVARTIS AG	-1.52%	+2.45%	+24.75%	+33.03%	28TCr
ASTRAZENECA PLC	-1.95%	-4.32%	+22.02%	+12.96%	28TCr
NOVO NORDISK A/S	-0.57%	+5.00%	-42.66%	-48.28%	20TCr
AMGEN INC.	-0.64%	+2.19%	+19.53%	+54.65%	19TCr
GILEAD SCIENCES, INC.	-0.66%	-3.26%	+11.82%	+56.87%	16TCr
Average	-1.00%	+0.64%	+14.80%	+34.71%	34.29TCr
Weighted average by Cap.	-1.07%	+1.03%	+27.45%	+67.12%

	2024	2025
Net sales	217.4Cr 32Cr 28Cr 25Cr 24Cr 45Cr 3.04TCr 45Cr 301.23Cr 117.67Cr 1.49TCr 120.54Cr 117.99Cr 5.14TCr	186.29Cr 28Cr 24Cr 22Cr 20Cr 38Cr 2.6TCr 39Cr 258.12Cr 100.83Cr 1.27TCr 103.29Cr 101.1Cr 4.41TCr
Net income	-32Cr -4.69Cr -4.04Cr -3.72Cr -3.49Cr -6.55Cr -442.95Cr -6.62Cr -44Cr -17Cr -216.92Cr -18Cr -17Cr -750.6Cr	-33Cr -4.87Cr -4.2Cr -3.86Cr -3.62Cr -6.81Cr -460.19Cr -6.87Cr -46Cr -18Cr -225.36Cr -18Cr -18Cr -779.82Cr
Net Debt	41Cr 6.07Cr 5.23Cr 4.82Cr 4.52Cr 8.49Cr 573.74Cr 8.57Cr 57Cr 22Cr 280.97Cr 23Cr 22Cr 972.24Cr	22Cr 3.21Cr 2.76Cr 2.54Cr 2.39Cr 4.48Cr 303.17Cr 4.53Cr 30Cr 12Cr 148.46Cr 12Cr 12Cr 513.73Cr

Guizhou Yibai Pharmaceutical Co., Ltd. Share Price

Stocks

600594

CNE000001H03

Pharmaceuticals

Valuation: Guizhou Yibai Pharmaceutical Co., Ltd.

Chart: Guizhou Yibai Pharmaceutical Co., Ltd.

Latest news : Guizhou Yibai Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Guizhou Yibai Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates